Evidence map›Paper›PMID 38642894›Full record

ArticleJournal of lipid research2024

Endogenous ether lipids differentially promote tumor aggressiveness by regulating the SK3 channel.

Marion Papin, Delphine Fontaine, Caroline Goupille, Sandy Figiel, Isabelle Domingo, Michelle Pinault, Cyrille Guimaraes, Nina Guyon, Pierre François Cartron, Patrick Emond and 11 more

Open access · goldAbstract read
In one paragraph

Article in Journal of lipid research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Multi-omics elucidation ofFrontiers in nutrition · 2025
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 3 institutions in 1 country.

Marion PapinNiche, Nutrition, Cancer & Oxidative metabolism (N2COx), UMR 1069, INSERM, University of Tours, Tours, France.
Delphine FontaineNiche, Nutrition, Cancer & Oxidative metabolism (N2COx), UMR 1069, INSERM, University of Tours, Tours, France.
Caroline GoupilleNiche, Nutrition, Cancer & Oxidative metabolism (N2COx), UMR 1069, INSERM, University of Tours, Tours, France; Department of Gynecology, CHRU Bretonneau, Tours, France.
Sandy FigielNiche, Nutrition, Cancer & Oxidative metabolism (N2COx), UMR 1069, INSERM, University of Tours, Tours, France.
Isabelle DomingoNiche, Nutrition, Cancer & Oxidative metabolism (N2COx), UMR 1069, INSERM, University of Tours, Tours, France.
Michelle PinaultNiche, Nutrition, Cancer & Oxidative metabolism (N2COx), UMR 1069, INSERM, University of Tours, Tours, France.
Cyrille GuimaraesNiche, Nutrition, Cancer & Oxidative metabolism (N2COx), UMR 1069, INSERM, University of Tours, Tours, France.
Nina GuyonCRCINA-INSERM 1232, Equipe « Apoptose et Progression tumorale », Nantes, France.
Pierre François CartronCRCINA-INSERM 1232, Equipe « Apoptose et Progression tumorale », Nantes, France.
Patrick EmondiBrain, UMR 1253, INSERM, Université de Tours, Tours, France; Nuclear medicine in vitro department, CHRU Bretonneau, Tours, France.
Antoine LefevreiBrain, UMR 1253, INSERM, Université de Tours, Tours, France.
Maxime GueguinouNiche, Nutrition, Cancer & Oxidative metabolism (N2COx), UMR 1069, INSERM, University of Tours, Tours, France.
David CrottèsNiche, Nutrition, Cancer & Oxidative metabolism (N2COx), UMR 1069, INSERM, University of Tours, Tours, France.
Paul-Alain JaffrèsLaboratoire Chimie Electrochimie Moléculaires et Chimie Analytique (CEMCA), UMR 6521, CNRS, University of Brest, Brest, France.
Lobna OuldamerNiche, Nutrition, Cancer & Oxidative metabolism (N2COx), UMR 1069, INSERM, University of Tours, Tours, France; Department of Gynecology, CHRU Bretonneau, Tours, France.
Karine MaheoNiche, Nutrition, Cancer & Oxidative metabolism (N2COx), UMR 1069, INSERM, University of Tours, Tours, France.
Gaëlle FromontNiche, Nutrition, Cancer & Oxidative metabolism (N2COx), UMR 1069, INSERM, University of Tours, Tours, France; Department of Pathology, CHRU Bretonneau, Tours, France.
Marie Potier-CartereauNiche, Nutrition, Cancer & Oxidative metabolism (N2COx), UMR 1069, INSERM, University of Tours, Tours, France.
Philippe BougnouxNiche, Nutrition, Cancer & Oxidative metabolism (N2COx), UMR 1069, INSERM, University of Tours, Tours, France.
Aurélie ChantômeNiche, Nutrition, Cancer & Oxidative metabolism (N2COx), UMR 1069, INSERM, University of Tours, Tours, France.
Christophe VandierNiche, Nutrition, Cancer & Oxidative metabolism (N2COx), UMR 1069, INSERM, University of Tours, Tours, France. Electronic address: christophe.vandier@univ-tours.fr.
Université de Tours · FRInserm · FRCentre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SK3 channels are potassium channels found to promote tumor aggressiveness. We have previously demonstrated that SK3 is regulated by synthetic ether lipids, but the role of endogenous ether lipids is unknown. Here, we have studied the role of endogenous alkyl- and alkenyl-ether lipids on SK3 channels and on the biology of cancer cells. Experiments revealed that the suppression of alkylglycerone phosphate synthase or plasmanylethanolamine desaturase 1, which are key enzymes for alkyl- and alkenyl-ether-lipid synthesis, respectively, decreased SK3 expression by increasing micro RNA (miR)-499 and miR-208 expression, leading to a decrease in SK3-dependent calcium entry, cell migration, and matrix metalloproteinase 9-dependent cell adhesion and invasion. We identified several ether lipids that promoted SK3 expression and found a differential role of alkyl- and alkenyl-ether lipids on SK3 activity. The expressions of alkylglycerone phosphate synthase, SK3, and miR were associated in clinical samples emphasizing the clinical consistency of our observations. To our knowledge, this is the first report showing that ether lipids differentially control tumor aggressiveness by regulating an ion channel. This insight provides new possibilities for therapeutic interventions, offering clinicians an opportunity to manipulate ion channel dysfunction by adjusting the composition of ether lipids.

Indexed as

Small-Conductance Calcium-Activated Potassium ChannelsCell Line, TumorCell MovementHumansLipidsMicroRNAsNeoplasm InvasivenessNeoplasmsKCNN3 protein, humanLipidsMicroRNAsSmall-Conductance Calcium-Activated Potassium Channelsether lipidsmiRNApotassium channelsSK3 channel

Identifiers

PMID38642894
PMCPMC11127165
OpenAlexW4394912766

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.